Phase 2 Enrollment Complete

CLX Ophthalmics announced today that the company had completed enrollment in CXL-005, its phase 2 study of EpiSmart epi-on cross-linking for corneal ecstasias. In total enrollment, the study was the largest cross-linking trial to date, and included patients with one of a number of diagnosed corneal ectasias. In an interim analysis of patients completed up to August 2018, patients showed statistically significant improvements in visual acuity at 6 months and 12 months post-EpiSmart treatment. Patients will complete the study in 6 months, and final results are expected in 2020.